Company intelligence / Profile preview

Aeonvital Biomedicine Research

Beijing, Beijing Shi, China

Ownership: Private
Development stage: Other

Overview

ReT01 ACT is in Phase 1 clinical trials for advanced solid tumors. The trial, started April 2024, is an open, single-arm study to evaluate safety and tolerance in patients with advanced solid tumors. No public efficacy results are available as of August 2025.

Therapeutic areas: Oncology
Modalities: Biological productsTIL therapy
Industry: Biotech

Partnerships

Beijing Anweisen Biomedicine Co., Ltd.

Beyond the preview

Go deeper on Aeonvital Biomedicine Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aeonvital Biomedicine Research.

Explore the full profile